Magnesium sulfate can more than halve the risk of life-threatening seizures during pregnancy when given to women with severe preeclampsia. Yet despite costing less than one dollar and being recognised as the gold-standard treatment, barriers such as supply chain gaps, substandard quality, late diagnosis and untrained staff prevent many women in low- and middle-income countries from accessing it when they need it.